Wall Street Zen Downgrades Verrica Pharmaceuticals (NASDAQ:VRCA) to Strong Sell

Posted by on Aug 17th, 2026

Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Saturday.

VRCA has been the topic of several other research reports. HC Wainwright started coverage on shares of Verrica Pharmaceuticals in a report on Tuesday, May 26th. They set a “buy” rating and a $12.00 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, July 15th. Finally, Zacks Research raised shares of Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Verrica Pharmaceuticals has an average rating of “Hold” and an average target price of $14.50.

View Our Latest Report on Verrica Pharmaceuticals

Verrica Pharmaceuticals Price Performance

Shares of VRCA opened at $4.97 on Friday. Verrica Pharmaceuticals has a 12-month low of $3.28 and a 12-month high of $9.82. The business’s fifty day moving average is $5.70 and its 200 day moving average is $5.95. The company has a quick ratio of 1.33, a current ratio of 1.45 and a debt-to-equity ratio of 0.18. The stock has a market cap of $85.38 million, a P/E ratio of -2.98 and a beta of 1.49.

Institutional Trading of Verrica Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Man Group plc purchased a new stake in Verrica Pharmaceuticals in the 4th quarter valued at about $94,000. Quadrature Capital Ltd bought a new stake in Verrica Pharmaceuticals in the 4th quarter valued at about $99,000. Bridgeway Capital Management LLC purchased a new stake in shares of Verrica Pharmaceuticals during the 3rd quarter valued at approximately $52,000. Beck Mack & Oliver LLC purchased a new stake in shares of Verrica Pharmaceuticals during the fourth quarter worth $100,000. Finally, XTX Topco Ltd bought a new position in Verrica Pharmaceuticals in the 4th quarter worth about $122,000. Institutional investors own 42.45% of the company’s stock.

About Verrica Pharmaceuticals

(Get Free Report)

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.

Featured Articles

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.